by Market Overview:
Antisense oligonucleotides are short single strands of nucleic acid polymers that bind specifically to their target messenger RNA (mRNA) through the mechanism of hybridization, thereby inhibiting gene expression or translation. They are used in drug development for various therapeutic applications such as neurodegenerative disorders, viral infections, and oncology.
Market key trends:
One of the major trends in the antisense oligonucleotides market is the rising focus on the development of next-generation antisense oligonucleotides. Traditional antisense oligonucleotides are based on phosphorothioate chemistry and exhibit non-specific toxicity issues. Hence, various pharmaceutical companies are focusing on developing next-generation antisense oligonucleotides such as PMOPlus, peptide nucleic acid (PNA), Morpholino, LNAplus etc. which exhibit improved potency, safety, and specificity. For instance, Wave Life Sciences is developing stereopure oligonucleotides that have superior binding affinity and potency against their biological targets compared to traditional antisense oligonucleotides. Stereopure oligonucleotides eliminate non-specific binding and off-target toxicities associated with traditional antisense oligonucleotides.
The antisense oligonucleotides market is witnessing high growth owing to the increasing development of advanced generation antisense oligonucleotides for treating both genetic as well as acquired diseases. Third generation antisense oligonucleotides have demonstrated high target specificity, efficacy and safety profile in clinical trials. Major companies are actively developing antisense therapeutics for rare neuromuscular and neurological disorders with significant unmet medical needs.
The global Antisense Oligonucleotides Market Share is estimated to be valued at US$ 2,913.5 Mn in 2023 and is expected to exhibit a CAGR of 6.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
SWOT Analysis
Strengths: Antisense oligonucleotides have demonstrated high precision and specificity in inhibiting target mRNA expression. These advanced drugs offer targeted treatment with minimal off-target effects.
Weaknesses: High development cost and lengthy clinical trials are major challenges. Commercialization of these precision medicines require extensive research and regulatory approvals.
Opportunities: Rising orphan drug designations and approval provides major market opportunities. Increasing success rates in clinical trials will further drive their adoption.
Threats: Biopharmaceuticals faces threat from biosimilars. Stringent regulations poses commercialization challenges.
Key Takeaways
The global antisense oligonucleotides market is expected to witness high growth, exhibiting CAGR of 6.6% over the forecast period, due to increasing R&D in oligonucleotide therapeutics and robust clinical pipeline.
Regional analysis:
North America dominated the global market in 2023 and is expected to maintain its lead over the forecast period. This is attributed to presence of major players and growing FDA approvals in the region. Europe is also a significant market supported by growing clinical research on oligonucleotides. Asia Pacific exhibits lucrative prospects for market growth with increasing healthcare investments.
Key players:
Key players operating in the antisense oligonucleotides market are Antisense Therapeutics, Biogen, Bio-Path Holdings, Ionis Pharmaceuticals, ProQR Therapeutics, Sarepta Therapeutics, Sterna Biologicals and Wave Life Sciences. Ionis Pharmaceuticals leads the market with strong portfolio and commercial sales of several antisense drugs. Other major companies are actively engaging in clinical research to develop oligonucleotide therapies for various genetic disorders.
*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it
